Yet another potentially profitable play regarding the Covid-19 pandemic is 
MRNA, A pharmaceutical company that is currently entering its 3rd phase of a corona Vaccine. While this play depends largely on its vaccine success over the rest of the month this could be an extremely lucrative play. It has been in a consolidation zone for the past few weeks, a Good buy in level is at $61-$63 and because of its heavy reliance on the performance of its vaccine to remain profitable I am keeping a tight stop loss. Anything over a 10% drop presents to much risk to feasibly call it worthwhile.
MRNA, A pharmaceutical company that is currently entering its 3rd phase of a corona Vaccine. While this play depends largely on its vaccine success over the rest of the month this could be an extremely lucrative play. It has been in a consolidation zone for the past few weeks, a Good buy in level is at $61-$63 and because of its heavy reliance on the performance of its vaccine to remain profitable I am keeping a tight stop loss. Anything over a 10% drop presents to much risk to feasibly call it worthwhile.
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。